ClinicalTrials.gg
RecruitingNCT06080789Updated Aug 5, 2026

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

A Phase 2 interventional study of RABI-767 in Acute Pancreatitis, sponsored by Panafina, Inc.. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Panafina, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.

Planned enrollment
65th of 97
36 · median 60
Started
2024
with 5 others
Phase 2
22 of 139
5 open now
Primary completion
2026-12
later than 11 of 48 live
Registered
114th of 139
by date

Among the 139 studies in Pancreatitis with a site in United States, this one is the 65th largest by planned enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2024, is one of 22 in phase 2, reaches primary completion later than 11 of the 48 other live ones, and was the 114th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Pancreatitis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.

The main question the study aims to answer is:

  • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis.

The study also aims to answer:

  • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis.

Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only.

The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.

03

Conditions studied

  • Acute Pancreatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of acute pancreatitis
  • Predicted severe acute pancreatitis, based on protocol defined criteria
  • Lack of improvement from status at admission, at the discretion of Investigator, at the time of randomization
  • Suitable for EUS-guided study drug administration procedure
  • Contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) of the abdomen/pancreas available for the evaluation of exclusion criteria

Key Exclusion Criteria:

  • Confirmed severe acute pancreatitis as defined by the Revised Atlanta Classification of Acute Pancreatitis (ie, Persistent [> 48 hours] organ failure, per Modified Marshall Score), prior to randomization
  • Anticipated discharge from hospital within 48 hours of randomization
  • More than 30% pancreatic necrosis on screening CECT or MRI
  • History of previous pancreatic necrosis, including necrosectomy
  • History of calcific chronic pancreatitis
  • Evidence of cholangitis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    RABI-767 plus Standard-of-Care

    Single-dose 125 mg RABI-767 plus standard-of-care

    Drug: RABI-767

  • No intervention
    Standard-of-Care Only

    No Intervention, Standard-of-Care Only

Interventions

  • DrugRABI-767

    125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the study intervention, regardless of its causal relationship to the study intervention. For the purposes of this study, any AE occurring in any study participant (regardless of treatment group assignment) at any time after enrollment/randomization, even if no study intervention has been administered, will be recorded.

    Time frame: Enrollment/Randomization to Day 28 (or hospital discharge, if earlier)

  2. Number of Participants with Serious Adverse Events

    A serious adverse event (SAE) is an AE, regardless of causality, that fulfills one or more protocol defined criteria for being serious.

    Time frame: Enrollment/Randomization to Day 35 Follow-up

  3. Change from Baseline in Clinical Chemistry Parameters

    Time frame: Baseline to Day 7

  4. Change from Baseline in Hematology Parameters

    Time frame: Baseline to Day 7

  5. Change from Baseline in Vital Signs

    Time frame: Baseline to Day 7

  6. Change from Baseline in Pulse Oximetry and Oxygen Delivery Measurements

    Time frame: Baseline to Day 7

Secondary outcomes

  1. Development of Severe Acute Pancreatitis

    Defined as \>48 hours persistent organ failure

    Time frame: Day 1 to Day 28 (or hospital discharge, if earlier)

  2. Development of New Onset Moderately Severe Acute Pancreatitis

    Defined as transient organ failure and/or local or systemic complications without persistent organ failure

    Time frame: Day 1 to Day 28 (or hospital discharge, if earlier)

  3. Development of Pancreatic Necrosis

    As identified on CECT/CEMRI imaging; may be further sub-grouped into \<30%, 30%-50%, and \>50% pancreatic necrosis, if data allow.

    Time frame: Baseline to Day 60 Follow-up

  4. Development of Local Complications of Acute Pancreatitis

    As identified on CECT/CEMRI imaging; may be further sub-grouped by type of complication, if data allow.

    Time frame: Baseline to Day 60 Follow-up

  5. Mortality due to acute pancreatitis and/or complications secondary to acute pancreatitis

    Death caused by acute pancreatitis and/or complications secondary to acute pancreatitis

    Time frame: Day 1 to Day 60 Follow-up

  6. Mortality due to any cause

    Death due to any cause

    Time frame: Day 1 to Day 60 Follow-up

  7. Days in Hospital

    Time frame: Day 1 through Day 28 (or hospital discharge, if earlier)

  8. Re-hospitalization for acute pancreatitis or related complications

    Number of participants re-hospitalized for acute pancreatitis or related complications out of total participants who are discharged.

    Time frame: From initial hospital discharge to Day 35 Follow-up

  9. Length of Stay in Intensive Care Unit

    Time frame: Day 1 through Day 28 (or hospital discharge, if earlier)

  10. Development of New Onset Infection

    May be further sub-grouped by: pancreatic, peripancreatic, and extra-pancreatic infections, as data allow.

    Time frame: Day 1 to Day 28 (or hospital discharge, if earlier)

  11. Change in Modified Marshall Score

    Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)

  12. Change in Sequential Organ Failure Assessment (SOFA) Score

    Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)

  13. Change in Systemic Inflammatory Response Syndrome (SIRS) Assessment

    Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)

  14. Change in Abdominal Pain Numeric Rating Score

    Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)

  15. Change in Computed Tomography Severity Index (CTSI) Score for Pancreatitis

    Time frame: From Baseline through Day 60 Follow-up

  16. Change in Modified Computed Tomography Severity Index (mCTSI) Score for Pancreatitis

    Time frame: From Baseline through Day 60 Follow-up

07

Study locations

15 of 16 sites recruiting
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
    Recruiting
    • Clinical Research Coordinator · Contact501-526-4860
  • Keck Hospital of USC and LA County Hospital
    Los Angeles, California 90033, United States
    Recruiting
    • Clinical Research Coordinator · Contact
    • · Contact323-409-6939
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
    • Clinical Research Coordinator · Contact303-724-1871
  • University of Florida Health
    Gainesville, Florida 32608, United States
    Recruiting
    • Clinical Research Coordinator · Contact352-273-9483
  • Orlando Health
    Orlando, Florida 32806, United States
    Recruiting
    • Clinical Research Coordinator · Contact321-841-6649
  • UI Health, University of Illinois Chicago Hospital Health Sciences System
    Chicago, Illinois 60612, United States
    Recruiting
    • Clinical Research Coordinator · Contact630-518-5456
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
    Withdrawn

    Not enrolling at this site.

  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Recruiting
    • Clinical Research Coordinator · Contact410-614-6708
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Recruiting
    • Clinical Research Coordinator · Contact313-746-8215
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
    Recruiting
    • Clinical Research Coordinator · Contact603-653-3651
  • NYU Langone Medical Center
    New York, New York 10016, United States
    Recruiting
    • Clinical Research Coordinator · Contact212-263-3095
  • Lisie Hospital
    Kochi, Kerala 682018, India
    Recruiting
    • Clinical Research Coordinator · Contact+91 859-095-8869
  • Christian Medical College (CMC) Vellore, Ranipet Campus
    Vellore, TamiNadu 632517, India
    Recruiting
    • Clinical Research Coordinator · Contact+91 987-249-3649
  • Postgraduate Institute of Medical Education and Research
    Chandigarh, India
    Recruiting
    • Clinical Research Coordinator · Contact
    • · Contact(+91) 9015143233
  • All India Institute of Medical Sciences
    Delhi, 110029, India
    Recruiting
    • Clinical Research Coordinator · Contact+91 941-160-2782
  • Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
    New Delhi, 110002, India
    Recruiting
    • Clinical Research Coordinator · Contact
    • · Contact+91 6205261118
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 22 phase 2 interventional studies under Pancreatitis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 110. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2023
First posted
Oct 12, 2023
StartActual
Jun 28, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06080789
Lead sponsor
Panafina, Inc.
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Jun 28, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 5, 2026

Study contacts

Kelly Abernathy
Contact
kabernathy@arrivobio.com
9194609500

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion